Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
September 25, 2018
Zogenix to Present at LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology
EMERYVILLE, Calif., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) ...
September 25, 2018
Paratek Pharmaceuticals Presenting New Omadacycline Data at IDWeek 2018
BOSTON, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (PRTK) announced today that new data from its omadacycline clinical and microbiology programs will be ...
September 25, 2018
Catalyst Biosciences to Present at Two Upcoming Healthcare Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology ...
September 25, 2018
Lipocine to Present at the Ladenburg Thalmann 2018 Healthcare Conference
SALT LAKE CITY, Sept. 25, 2018 /PRNewswire/ -- Lipocine Inc. (LPCN), a specialty pharmaceutical company, announced today that Dr. Mahesh Patel, Chairman, President and CEO, will ...
September 25, 2018
BioDelivery Sciences to Present at the Cantor Fitzgerald Global Healthcare Conference and the Ladenburg Thalmann 2018 Healthcare Conference
RALEIGH, N.C., Sept. 25, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (BDSI), a rapidly growing commercial stage specialty pharmaceutical company dedicated to patients living ...
September 25, 2018
Vaccinex, Inc. to Present at the Ladenburg Thalmann 2018 Healthcare Conference
ROCHESTER, N.Y., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (VCNX), a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat ...
September 25, 2018
Theravance Biopharma to Present at the 2018 Cantor Global Healthcare Conference
DUBLIN, Sept. 25, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) announced today that members of management will present a corporate overview at the 2018 Cantor Global ...
September 25, 2018
Opiant Pharmaceuticals Announces Pricing of Public Offering of Common Stock
SANTA MONICA, Calif., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and drug abuse, ...
September 25, 2018
Molecular Templates, Inc. Announces Closing of Public Offering of Common Stock and the Full Exercise of the Underwriters’ Option to Purchase Additional Shares
AUSTIN, Texas, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (MTEM) (“Molecular”), a clinical-stage oncology company focused on the discovery and development of proprietary engineered ...
September 25, 2018
Y-mAbs Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
NEW YORK, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (YMAB) a late-stage clinical biopharmaceutical company focused on the development ...
September 25, 2018
Kuros Biosciences Appoints Strategic Advisory Board
SCHLIEREN (ZURICH), Switzerland, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Kuros Biosciences (SIX:KURN) today announced the formation of its Strategic Advisory Board (SAB). The newly-formed SAB ...
September 24, 2018
Gemphire Therapeutics Announces Workforce Reduction
LIVONIA, Mich., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, ...
September 24, 2018
4D Announces Positive Data From Phase 1b Study of Thetanix in Paediatric Crohn's Diseases Patients and Publication of Studies Showing Strong Efficacy of Thetanix in Preclinical Models of IBD
LEEDS, United Kingdom, Sept. 24, 2018 (GLOBE NEWSWIRE) -- 4D pharma plc (DDDD.L), a pharmaceutical company leading the development of live biotherapeutics, today announces positive ...
September 24, 2018
ProQR Announces Presentations at the OTS Annual Meeting
LEIDEN, the Netherlands, Sept. 24, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (PRQR), a company dedicated to changing lives through the creation of transformative RNA ...
September 24, 2018
MediWound Awarded Additional BARDA Contract Valued Up to $43 Million for Development of NexoBrid® for Sulfur Mustard Injuries
YAVNE, Israel, Sept. 24, 2018 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe ...
September 24, 2018
MannKind Announces Completion of Cohort 1 and Opens Enrollment for Cohort 2 of Afrezza® Safety and Pharmacokinetics Study in Pediatric Patients
WESTLAKE VILLAGE, Calif., Sept. 24, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD) announced today that Cohort 2 of the Afrezza® safety and pharmacokinetics study in ...
September 24, 2018
Arrowhead Pharmaceuticals to Host R&D Day on Emerging Pipeline of RNAi Therapeutics
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (ARWR) today announced that it will host a Research & Development (R&D) Day to discuss its emerging pipeline of RNAi ...
September 24, 2018
AzurRx BioPharma Announces Positive Outcome with MS1819-SD Showing Statistically Significant Efficacy in a Phase IIa Exocrine Pancreatic Insufficiency Trial in Chronic Pancreatitis
NEW YORK, Sept. 24, 2018 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies ...
September 24, 2018
Eiger Announces FDA Guidance on HDV Phase 3 Study Design: Primary Endpoint Established; D-LIVR Study Initiating Q4 2018
PALO ALTO, Calif., Sept. 24, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today ...
September 24, 2018
Altimmune Awarded $2.5 Million in Additional BARDA Funding to Support NasoShield™ Development
GAITHERSBURG, Md., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (ALT), a clinical-stage immunotherapeutics company, today announced that the Biomedical Advanced Research and Development Authority (BARDA) ...
Page 16 of 117